Profiling Biology at Scale with DRUG-seq: From Mechanisms to Safety

Traditional discovery approaches force a trade-off: deep biological resolution for a few perturbations or broad screens with limited endpoints.

This webinar explores how a high-throughput transcriptomics assay addresses this challenge by enabling genome-wide expression profiling at an industrial scale, supporting the discovery of mechanisms of action, pathway analysis and therapeutic safety assessment.

Attendees will explore how broad compound profiling in primary human cells supports clustering by mechanism, uncovers shared and divergent regulatory programs and enables data-rich screening.

The session will also examine how transcriptomic responses to perturbations can reveal off-target effects in RNAi therapeutics, moving beyond simple knockdown measurements.

The featured speakers will highlight how high-resolution transcriptomic data improves model building, predictive toxicology and large-scale screening, providing both breadth and depth in early-stage research.

Register for this webinar to learn how transcriptomics assays are transforming data-driven drug discovery.

Speakers

George Pilitsis, Director, Product, Ginkgo Datapoints

George Pilitsis is the Director of Product at Ginkgo Datapoints overseeing strategy, product development and customer delivery with a focus on generating large perturbation data in Drug Discovery. Prior to Ginkgo, George was a consultant at Deloitte Consulting LLP working across the drug discovery and development spectrum. Most notably, he developed and implemented the global launch readiness plan for one of the COVID-19 vaccines, and co-developed an AI platform to process product quality complaints. He holds a degree in Chemical Engineering and Economics.

Message Presenter

Ayla Ergun, Sr. Director, Computational Biology & AI, Ginkgo Datapoints

Ayla Ergun is a computational biologist leading the perturbation response profiling platform at Ginkgo Datapoints. Ayla obtained her PhD in Biomedical Engineering, and specializes in leveraging large-scale transcriptomics datasets and systems biology for target identification and prioritization. Ayla is committed to utilizing disease-relevant multiomic and high-throughput screening data and leveraging computational tools to discover disease-modifying treatments.

Message Presenter

Kurt Cox, Senior Engineer, Ginkgo Datapoints

Kurt Cox is a Senior Scientist working within the functional genomics screening platform at Ginkgo Datapoints. Kurt obtained his PhD in Biological Chemistry from MIT and completed his postdoctoral studies at the Broad Institute before joining the Chemical Biology and Proteomics group at Biogen for five years. His background spans the use and development of chemical and enzymatic methods toward understanding molecular mechanisms of action and cellular function from a proteomic lens, as well as applying CRISPR screens toward cell engineering projects.

Message Presenter

Sarah Boswell, Sequencing Group Lead, Ginkgo Datapoints

Sarah Boswell is the Sequencing Group Lead at Ginkgo Datapoints. Sarah obtained her PhD in Chemistry and completed postdoctoral studies at Massachusetts General Hospital. Prior to joining Ginkgo, she served as the Director of Sequencing Technologies and the Director of the Single Cell Core at Harvard Medical School. Her background spans the development and application of next-generation sequencing (NGS) assays, specializing in high-throughput RNA sequencing (including Bulk RNA-seq, scRNA-seq, and DRUG-seq), new method onboarding, and supporting sequencing applications for diverse model systems.

Message Presenter